3. Antidiabetic Agents

Antidiabetic agents and vascular events.

TEACHERS’ TOPICS Insulin and Oral Antidiabetic Agents

The current manuscript describes an overview for therapeutic approaches to treat diabetes mellitus. Detailed presentation of the role of insulin in both disease state development and therapy is given. The article also addresses the classification, chemistry, pharmacokinetic properties, dosage forms, mechanisms of action, and therapeutic indications of oral anti-diabetic agents currently availab...

Gliptins: A New Class of Oral Antidiabetic Agents

India has the largest population of patients with type 2 diabetes mellitus. The conventional agents used to treat type 2 diabetes frequently exhibit reduced efficacy over time leading to inadequate glycaemic control and are also associated with adverse effects. Hence, there is a need for alternative therapies that can overcome the limitations associated with conventional antidiabetic agents. Th...

Antidiabetic and antimalarial biguanide drugs are metal-interactive antiproteolytic agents.

Various biguanide derivatives are used as antihyperglycemic and antimalarial drugs (e.g., 1,1-dimethyl biguanide (metformin), phenylethyl biguanide (phenformin), N-(4-chlorophenyl)-N'-(isopropyl)-imidodicarbonimidic diamide (proguanil)); however, no common mechanism has been suggested in these controversial therapeutic actions. Biguanides bind endogenous metals that inhibit cysteine proteases i...

Safe Oral Antidiabetic Agents in Cardiac Patients: An Update

Cardiovascular disease is the major cause of mortality among patients with type 2 diabetes mellitus, accounting for 60-80% of death in these patients. Despite recent studies demonstrating likely benefit of good glycaemic control in decreasing cardiovascular risk in type 2 DM, there have been lingering concerns about potential adverse cardiovascular effects of insulin secretagogues, specifically...